Collin Nzunda

Collin Nzunda

Auto-generated profile, based on publicly available information

Collin Nzunda

Department of Haematology and Blood Transfusion, Muhimbili University of Health and Allied Sciences , United Nations Road, Upanga West District, P.O. Box 65001, Dar es Salaam

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2025 in The Pharmacogenomics Journal
Verified
Journal Article
Closed access
PDF file
SNSiana Nkya
Siana Nkya
CNCollin Nzunda
Collin Nzunda
ESEmmanuel Saukiwa
Emmanuel Saukiwa
FKFrida Kaywanga
Frida Kaywanga
EBEliud Buchard
Eliud Buchard
JMJulie Makani
Julie Makani

18 July 2024 in BMC Medical Genomics
Verified
Journal Article
Open access
SNSiana Nkya
Siana Nkya
CNCollin Nzunda
Collin Nzunda
ESEmmanuel Saukiwa
Emmanuel Saukiwa
FKFrida Kaywanga
Frida Kaywanga
EBEliud Buberwa
Eliud Buberwa
JMJulie Makani
Julie Makani
Background: Pharmacogenomics of hydroxyurea is an important aspect in the management of sickle cell disease (SCD), especially in the era of genomic medicine. Genetic variations in loci associated with HbF induction and drug metabolism are prime targets for hydroxyurea (HU) pharmacogenomics, as these can significantly impact the therapeutic efficacy and safety of HU in SCD patients. Methods: This study involved designing of a custom panel targeting BCL11A, ARG2, HBB, HBG1, WAC, HBG2, HAO2, MYB, SAR1A, KLF10, CYP2C9, CYP2E1 and NOS1 as potential HU pharmacogenomics targets. These genes were selected based on their known roles in HbF induction and HU metabolism. The panel was designed using the Illumina Design Studio (Illumina, San Diego, CA, USA) and achieved a total coverage of 96% of all genomic targets over a span of 51.6 kilobases (kb). This custom panel was then sequenced using the Illumina MiSeq platform to ensure high coverage and accuracy. Results: We are reporting a successfully designed Illumina (MiSeq) HU pharmacogenomics custom panel encompassing 51.6 kilobases. The designed panel achieved greater than 1000x amplicon coverage which is sufficient for genomic analysis. Conclusions: This study provides a valuable tool for research in HU pharmacogenomics, especially in Africa where SCD is highly prevalent, and personalized medicine approaches are crucial for improving patient outcomes. The custom-designed Illumina (MiSeq) panel, with its extensive coverage and high sequencing depth, provides a robust platform for studying genetic variations associated with HU response. This panel can contribute to the development of tailored therapeutic strategies, ultimately enhancing the management of SCD through more effective and safer use of hydroxyurea.

17 March 2026 in Blood Global Hematology
Verified
Journal Article
Open access
ANAhlam MOHAMED Nasser
Ahlam MOHAMED Nasser
EMElia J. Mmbaga
Elia J. Mmbaga
HIHamisa Iddy
Hamisa Iddy
CMCaroline Mollel
Caroline Mollel
CNCollin Nzunda
Collin Nzunda
NSNeil P. Shah
Neil P. Shah

25 August 2023 in Research Square
Verified
Preprint
Open access
PDF file
SNSiana Nkya
Siana Nkya
CNCollin Nzunda
Collin Nzunda
ESEmmanuel Saukiwa
Emmanuel Saukiwa
FKFrida Kaywanga
Frida Kaywanga
EBEliud Buchard
Eliud Buchard
JMJulie Makani
Julie Makani
Pharmacogenomics of hydroxyurea is an important aspect in the management of sickle cell disease (SCD), especially in the era of genomic medicine. Genetic variations in loci associated with HbF induction and drug metabolism are prime targets for hydroxyurea (HU) pharmacogenomics. This study investigated genetic variations in BCL11A, ARG2, HBB, HBG1, WAC, HBG2, HAO2, MYB, SAR1A, KLF10, CYP2C9, CYP2E1 and NOS1 as potential HU pharmacogenomics targets. The panel was designed using the Illumina Design Studio (Illumina, San Diego, CA, USA) and achieved a total coverage of 96% of all genomic targets over a span of 51.6 kilobases (kb). We are reporting a successfully designed Illumina (MiSeq) HU pharmacogenomics custom panel encompassing 51.6 kilobases. The designed panel achieved greater than 1000x amplicon coverage which is which is sufficient for genomic analysis. Therefore, this study provides a valuable tool for research in HU pharmacogenomics, especially in Africa.

27 July 2026 in Blood Global Hematology
Verified
Journal Article
Open access
CNCollin Nzunda
Collin Nzunda
DKDoreen Donald Kamori
Doreen Donald Kamori
ANAhlam MOHAMED Nasser
Ahlam MOHAMED Nasser
CCClara Chamba
Clara Chamba
EBEliud Buchard
Eliud Buchard
WMWilliam Mawalla
William Mawalla

27 May 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
SNSiana Nkya
Siana Nkya
CNCollin Nzunda
Collin Nzunda
ESEmmanuel Saukiwa
Emmanuel Saukiwa
FKFrida Kaywanga
Frida Kaywanga
EBEliud Buchard
Eliud Buchard
JMJulie Makani
Julie Makani
Sickle cell disease (SCD) continues to pose a significant public health challenge, particularly in sub-Saharan Africa. Despite its discovery over a century ago, the progress in developing and accessing effective interventions has been notably restricted. Currently, hydroxyurea stands as the primary drug in widespread use, and has been associated with elevated levels of fetal hemoglobin (HbF) and enhanced clinical outcomes. Notably, a substantial proportion, up to 30%, of patients do not exhibit a positive response to hydroxyurea treatment. There is compelling evidence suggesting that genetic factors play a crucial role in influencing the effectiveness of hydroxyurea. In this study, we present findings on the investigation of genetic variants influencing hydroxyurea response in 13 genetic loci associated with HbF synthesis and hydroxyurea drug metabolism focusing on MYB , HBB , HBG1 , HBG2 , BCL11A , KLF10 , HAO2 , NOS1 , ARG2 , SAR1A , CYP2C9 , CYP2E1 . We report remarkable genetic associations with CYP2C9 , CYP2E1, KLF10 , BCL11A , ARG2 , HBG1 , SAR1A , MYB , and NOS1 loci with hydroxyurea response. We also highlight associated pathway’s enrichment and gene-gene interactions analysis in the context of hydroxyurea treatment response.